Market: NYQ |
Currency:
Address:
📈 RAL Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$47.55
-
Upside/Downside from Analyst Target:
-11.51%
-
Broker Call:
12
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
-
-
Net Income Growth Range (1Y):
-
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
-
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for RAL
No earnings history available for this symbol.
📰 Related News & Research
-
Braze, Inc. Announces Retirement of General Counsel Susan Wiseman in April 2026 8-K Filing
April 7, 2026
BRAZE, INC. ANNOUNCES RETIREMENT OF GENERAL COUNSEL AND CORP...
-
ConnectM Appoints Brigadier General Mark G. Beesley to Accelerate $50B+ Defense Sector Expansion with AI and Energy Solutions
April 7, 2026
ConnectM Technology Solutions Appoints Retired Brigadier Gen...
-
General Fusion and Spring Valley Acquisition Corp III Announce SPAC Merger to Advance Commercial Fusion Energy: Technology, Market Opportunity, and Investment Highlights 7891213
April 7, 2026
General Fusion: Investor Update on SPAC Merger and Commercia...
-
Mach Natural Resources LP Acquires IKAV and Sabinal Oil & Gas Assets: Pro Forma Financials and Reserve Highlights for 2025
April 7, 2026
Mach Natural Resources LP Announces Major Acquisitions, Expa...
-
Tennessee Piedmont Natural Gas Business Sold by Duke Energy to Spire for $2.48 Billion: Abbreviated Financial Statements and Regulatory Overview
April 7, 2026
Spire Inc. to Acquire Tennessee Piedmont Natural Gas Busines...
-
MISC Berhad 2026 Outlook: Crude Tanker Rally, LNGC Risks & Target Price Analysis
April 6, 2026
Broker: UOB Kay Hian Date of Report: 6 April 2026 Excerpt f...
-
Denali Therapeutics Regains Full Rights to DNL593 for Frontotemporal Dementia, Phase 1/2 Results Expected by End of 2026
April 4, 2026
Denali Therapeutics Regains Full Rights to DNL593 for FTD-GR...
-
Gibraltar Industries, Inc. Files Form 8-K with SEC – Company Details, Address, and Stock Information (April 3, 2026) 151651
April 4, 2026
Gibraltar Industries Announces Special Executive Bonuses Lin...
-
Sunshine Biopharma Inc. 2025 Annual Report: Generic Drug Portfolio, Proprietary Oncology & Antiviral Developments, and Corporate Strategy
April 4, 2026
Sunshine Biopharma Inc. 2025 Annual Report - Investor Analys...
-
Ascent Bridge Limited Announces Sale of MTBL Cultural Centre Pte. Ltd. to Nyonya Heritage Pte. Ltd. for S$59,532.92 – Disclosable Transaction Under SGX Rules 1
April 3, 2026
Ascent Bridge Limited Announces Disposal of Wholly Owned Sub...
🔍 View more Reports